CCNE1 Is a Novel Synthetic Lethal Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma

被引：0
|
作者：
Kawahara, Naoki [1 ]
Yamada, Yuki [1 ]
Kawaguchi, Ryuji [1 ]
机构：
[1] Nara Med Univ, Dept Obstet & Gynecol, Nara, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3026
引用
收藏
页码：1845 / 1845
页数：1
相关论文
共 50 条
  • [21] ARID1A-mutated ovarian cancers depend on HDAC6 activity
    Bitler, Benjamin G.
    Wu, Shuai
    Park, Pyoung Hwa
    Hai, Yang
    Aird, Katherine M.
    Wang, Yemin
    Zhai, Yali
    Kossenkov, Andrew V.
    Vara-Ailor, Ana
    Rauscher, Frank J., III
    Zou, Weiping
    Speicher, David W.
    Huntsman, David G.
    Conejo-Garcia, Jose R.
    Cho, Kathleen R.
    Christianson, David W.
    Zhang, Rugang
    NATURE CELL BIOLOGY, 2017, 19 (08) : 962 - +
  • [22] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated ovarian cancers.
    Bitler, Benjamin
    Shih, Le-Ming
    Zhang, Rugang
    CLINICAL CANCER RESEARCH, 2016, 22
  • [23] A key HDAC6 dependency of ARID1A-mutated ovarian cancer
    Lucia Altucci
    Nature Cell Biology, 2017, 19 : 889 - 890
  • [24] EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer
    Briggs, Kimberly J.
    Min, Chengyin
    Zhang, Hongxiang
    Huang, Alan
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Synthetic lethal strategy of an EZH1/2 dual inhibitor, HM97662, for the treatment of ARID1A-mutated solid cancers
    Kim, Yu-Yon
    Jung, Seung Hyun
    Han, Seon Yeong
    Byun, Jooyun
    Lee, Gunwoo
    Lee, Miyoung
    Park, Junghwa
    Kong, Taeyeon
    Han, Hyesun
    Lee, Sang Hyun
    Ahn, Young Gil
    CANCER RESEARCH, 2024, 84 (06)
  • [26] Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC)
    Miller, R. E.
    Bajrami, I.
    Brough, R.
    Konde, A.
    Campbell, J.
    Rafiq, R.
    Ashworth, A.
    Lord, C. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 103 - 104
  • [27] Gene Amplification CCNE1 Is Related to Poor Survival and Potential Therapeutic Target in Ovarian Cancer
    Nakayama, Naomi
    Nakayama, Kentaro
    Shamima, Yeasmin
    Ishikawa, Masako
    Katagiri, Atsuko
    Iida, Kouji
    Miyazaki, Khoji
    CANCER, 2010, 116 (11) : 2621 - 2634
  • [28] Targeted therapy concepts for ARID1A-mutated colon cancer cell lines
    Xu, S.
    Sak, A.
    Niedermaier, B.
    Erol, B. Y.
    Groneberg, M.
    Stuschke, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S192 - S192
  • [29] SMARCA4 loss irrelevant for ARID1A mutated ovarian clear cell carcinoma: A case report
    Wagner, Samantha Kay
    Moon, Ashley S.
    Howitt, Brooke E.
    Renz, Malte
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 50
  • [30] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
    Benjamin G Bitler
    Katherine M Aird
    Azat Garipov
    Hua Li
    Michael Amatangelo
    Andrew V Kossenkov
    David C Schultz
    Qin Liu
    Ie-Ming Shih
    Jose R Conejo-Garcia
    David W Speicher
    Rugang Zhang
    Nature Medicine, 2015, 21 : 231 - 238
12345